NASDAQ:EXAS 19 November 2025

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares were last up 0.1% at $109.43 on Monday after Barclays lowered its 12-month target price to $142 from $169, citing reduced estimates and a lower valuation multiple but keeping an Overweight rating. A price target is an analyst estimate; Overweight signals it expects the stock to outperform its coverage universe.

2 February 2026

Biotechnology·NASDAQ:EXAS·NYSE:ABT·Stock Market

Abbott stock jumps 3% into the weekend as Wall Street resets targets after earnings wobble

Abbott Laboratories shares ended Friday roughly 3% higher, closing at $109.30. The stock had dipped to a session low around $105.72 earlier, with volume picking up noticeably as traders wrapped up the week.

31 January 2026

Earnings Reports·NASDAQ:EXAS·NYSE:ABT·Stock Market

Abbott stock rebounds as Exact Sciences vote nears after broker upgrade

Abbott Laboratories shares climbed roughly 2.6%, closing in on $108.89 Friday afternoon after earlier dipping to $105.72. The stock hit a peak of $109.34 during the session.

30 January 2026

Mergers and Acquisitions·NASDAQ:EXAS·NYSE:ABT·Stock Market

Abbott stock price steadies near a 52-week low as upgrade talk meets nutrition worries

Abbott Laboratories shares ticked up 0.3%, reaching $106.34 in Thursday afternoon trading, following a choppy week that held the healthcare giant close to its recent lows.

29 January 2026

NASDAQ:EXAS·NYSE:ABT·Stock Market

Abbott stock rises after CEO Robert Ford buys $2 million in shares — what ABT investors watch next

Abbott Laboratories saw its shares climb roughly 1.3% on Monday, closing near $108.77 in after-hours trading. A recent filing revealed that Chairman and CEO Robert B. Ford acquired 18,800 shares at an average price of $107.1259.

27 January 2026

NASDAQ:ABT·NASDAQ:EXAS·Stock Market

Abbott Laboratories stock (ABT) in focus: Exact Sciences vote date lands as earnings week nears

Abbott Laboratories starts the week with its proposed acquisition of Exact Sciences in the spotlight, following Exact Sciences’ announcement of a shareholder vote scheduled for Feb. 20.

11 January 2026

Earnings Reports·NASDAQ:EXAS·NYSE:ABT

Abbott stock today: ABT rises as Exact Sciences deal filing and Volt AFib device stay in focus

Abbott Laboratories shares rose 0.97% to $125.78 in Tuesday’s regular session and held steady in after-hours trading. ABT quote

31 December 2025

NASDAQ:EXAS·NYSE:ABT

Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now

Exact Sciences Corporation has turned into one of the most closely watched healthcare stocks heading into December 2025, thanks to a blockbuster takeover agreement with Abbott Laboratories, strong Q3 results, and a rapid share‑price rally that has pushed EXAS to all‑time highs. As of mid‑day on December 1, 2025, the stock trades around $101 per share, just below the agreed $105 per‑share cash buyout price. Exact Sciences Investor Relations+1

1 December 2025

Mergers & Acquisitions·NASDAQ:EXAS·Stock Market

Exact Sciences (EXAS) Stock Today: Analyst Downgrades, Abbott’s $21 Billion Takeover and Legal Scrutiny – 25 November 2025

Exact Sciences Corporation is trading near record highs as Wall Street shifts to “Hold,” merger-arb funds move in and shareholder lawyers start circling Abbott’s $21 billion bid.

25 November 2025

Mergers and Acquisitions·NASDAQ:EXAS·NYSE:ABT

Exact Sciences (EXAS) Stock Today, November 24, 2025: Abbott Buyout Spread, Analyst Downgrades and UBS Target Hike

Exact Sciences Corporation stock is trading calmly near its takeover price today as Wall Street digests a flood of fresh analyst calls, legal scrutiny and local reaction to Abbott Laboratories’ multi‑billion‑dollar bid for the cancer‑diagnostics specialist.

24 November 2025

Mergers and Acquisitions·NASDAQ:EXAS·NYSE:ABT

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation in an all‑cash transaction valuing the target at about $21 billion in equity and roughly $23 billion including debt. Reuters+2PR Newswire+2

20 November 2025

Mergers & Acquisitions·NASDAQ:EXAS·NYSE:ABT

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom+2Reuters+2

20 November 2025

Mergers & Acquisitions·NASDAQ:EXAS·NYSE:ABT

EXAS Stock Soars on Abbott Takeover Talks: Exact Sciences Jumps Over 20% on November 19, 2025

Exact Sciences Corporation is surging today after reports that healthcare giant Abbott Laboratories is in advanced talks to acquire the cancer diagnostics specialist. Shares of EXAS spiked sharply intraday, briefly approaching new 52‑week highs as traders rushed into the name on renewed takeover speculation. Reuters+2Investing.com+2

19 November 2025

Mergers & Acquisitions·NASDAQ:EXAS·Stock Market

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire cancer diagnostics specialist Exact Sciences, in what could be the healthcare giant’s largest deal in nearly a decade and a major shake-up for the global cancer testing market.Bloomberg+1

19 November 2025

Mergers & Acquisitions·NASDAQ:EXAS·NYSE:ABT·Stock Market

NASDAQ:EXAS 19 November 2025 - 2 February 2026